ABION Inc. (KOSDAQ: 203400)

Market Cap	201.80B
Revenue (ttm)	1.33B
Net Income (ttm)	-47.39B
Shares Out	25.22M
EPS (ttm)	-2,255.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,173
Open	8,140.00
Previous Close	8,110.00
Day's Range	8,020.00 - 8,190.00
52-Week Range	4,710.00 - 13,000.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About ABION

ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers; ABN201, an antibody cytokine fusion protein to treat solid cancers; and ABN101, a dry powder inhaler as a prophylactic treatment for various re...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 38
• Stock Exchange: KOSDAQ
• Ticker Symbol: 203400

Financial Performance

In 2023, ABION's revenue was 1.27 billion, a decrease of -49.16% compared to the previous year's 2.51 billion. Losses were -29.21 billion, 46.6% more than in 2022.